Piper Sandler Boosts Masimo (NASDAQ:MASI) Price Target to $210.00

Masimo (NASDAQ:MASI) had its target price lifted by Piper Sandler from $180.00 to $210.00 in a research note issued on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the medical equipment provider’s stock. Piper Sandler’s price target would suggest a potential upside of 20.15% from the stock’s previous close.

Other equities research analysts also recently issued research reports about the stock. Raymond James upgraded shares of Masimo from a “market perform” rating to an “outperform” rating and set a $170.00 price target for the company in a research report on Wednesday, November 6th. Wells Fargo & Company increased their target price on Masimo from $171.00 to $193.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a report on Wednesday, November 6th. BTIG Research increased their price objective on Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $190.00 target price (up previously from $170.00) on shares of Masimo in a research note on Friday, November 22nd. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $175.67.

Masimo Price Performance

Masimo stock traded up $0.71 during mid-day trading on Wednesday, hitting $174.78. The company’s stock had a trading volume of 204,001 shares, compared to its average volume of 662,268. The stock has a market capitalization of $9.36 billion, a P/E ratio of 120.32 and a beta of 1.01. Masimo has a twelve month low of $101.61 and a twelve month high of $180.97. The stock’s fifty day moving average price is $158.77 and its two-hundred day moving average price is $133.93. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50.

Masimo (NASDAQ:MASI) last announced its earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 EPS for the quarter, beating the consensus estimate of $0.84 by $0.14. The business had revenue of $504.60 million during the quarter, compared to the consensus estimate of $502.87 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. Masimo’s revenue was up 5.4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.63 earnings per share. Research analysts forecast that Masimo will post 4.03 earnings per share for the current year.

Institutional Trading of Masimo

A number of institutional investors have recently added to or reduced their stakes in MASI. NBC Securities Inc. lifted its stake in shares of Masimo by 47.1% in the third quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock worth $30,000 after buying an additional 73 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its holdings in Masimo by 133.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider’s stock valued at $44,000 after acquiring an additional 200 shares during the period. HHM Wealth Advisors LLC boosted its holdings in Masimo by 25.0% during the second quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider’s stock valued at $79,000 after acquiring an additional 125 shares during the period. Fifth Third Bancorp increased its stake in shares of Masimo by 16.4% in the second quarter. Fifth Third Bancorp now owns 695 shares of the medical equipment provider’s stock worth $88,000 after purchasing an additional 98 shares during the period. Finally, Headlands Technologies LLC bought a new position in shares of Masimo in the second quarter worth about $109,000. 85.96% of the stock is currently owned by institutional investors and hedge funds.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.